How Much Does Prolia (Denosumab) Cost in Montana in 2026?

Montana Cash-Pay Pricing for Prolia in 2026

The average cash-pay price for a single Prolia injection across Montana retail pharmacies sits at approximately $1,500 in 2026, matching Amgen's national list price. Because denosumab is dosed once every six months as a 60 mg subcutaneous injection, uninsured patients face a total annual cost near $3,000 for the brand-name product alone 1.

Why Montana Prices Track the National Average

Montana's relatively small population and limited pharmacy competition mean that retail pricing rarely dips below the manufacturer's wholesale acquisition cost. Unlike oral bisphosphonates such as generic alendronate (which can cost under $15 per month), denosumab is a biologic monoclonal antibody produced through recombinant DNA technology. That manufacturing complexity keeps the floor price high.

Where Price Variation Exists

Hospital outpatient infusion centers, specialty pharmacies, and independent compounding pharmacies each set different markups. A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that buy-and-bill pricing for physician-administered biologics varied by as much as 30% across rural and urban settings 2. Montana patients in Billings or Missoula may see slightly different facility fees compared to those in smaller communities like Havre or Miles City.

Patients paying entirely out of pocket should call at least three pharmacies or infusion centers to compare total costs, including the drug price and any administration fees.

Montana Medicaid and Prolia Coverage

Montana Medicaid does not cover Prolia for the osteoporosis indication as of 2026. This exclusion applies to both fee-for-service Medicaid and Montana's Medicaid expansion population.

What the Exclusion Means in Practice

Medicaid programs maintain preferred drug lists (PDLs), and each state negotiates coverage independently. Montana's PDL directs osteoporosis patients toward first-line agents like generic alendronate or risedronate before considering injectable biologics. The state has not added denosumab to its PDL for the osteoporosis indication.

Possible Exceptions

Medicaid may cover denosumab under different diagnosis codes. For example, patients receiving androgen-deprivation therapy for prostate cancer or aromatase-inhibitor therapy for breast cancer who face treatment-induced bone loss might qualify under oncology-related prior authorization pathways. Coverage determinations are diagnosis-specific, so patients and prescribers should submit prior authorization requests referencing the exact clinical scenario.

Montana Medicaid recipients with osteoporosis who have failed or cannot tolerate oral bisphosphonates should work with their prescriber to document the clinical rationale. A formal appeal citing the FREEDOM trial data, which demonstrated a 68% reduction in vertebral fractures with denosumab versus placebo over 36 months (N=7,868) 3, may strengthen the case for an exception.

Commercial Insurance Coverage in Montana

Most major commercial insurers operating in Montana cover Prolia, though cost-sharing structures vary widely. Plans from Blue Cross Blue Shield of Montana, PacificSource, and UnitedHealthcare typically classify denosumab as a specialty medication or a medical benefit (buy-and-bill), depending on how the injection is administered.

Medical Benefit vs. Pharmacy Benefit

When a physician or nurse administers the injection in a clinic, insurance processes the claim under the medical benefit (often Part B for Medicare-equivalent commercial plans). This route frequently results in lower patient copays because the drug and administration are bundled into a single office-visit claim.

When the drug is dispensed through a specialty pharmacy for self-administration (less common with denosumab), it falls under the pharmacy benefit, which may carry a separate specialty-tier copay of 20% to 40%.

Typical Out-of-Pocket Costs With Insurance

Commercially insured patients in Montana commonly pay between $0 and $300 per injection after plan benefits apply. A 2024 IQVIA report estimated that the median commercial copay for denosumab nationally was $75 per injection for patients with specialty-tier coverage 4. Patients with high-deductible health plans (HDHPs) may owe the full list price until they meet their annual deductible.

Patients should verify whether their plan requires prior authorization or step therapy (trying a bisphosphonate first) before approving denosumab.

Medicare Part B Coverage in Montana

Medicare Part B generally covers Prolia as a physician-administered injectable. The standard cost-sharing structure assigns 80% to Medicare and 20% to the patient after the Part B deductible is met.

Calculating the Patient's Share

With a list price of $1,500, the 20% coinsurance would be approximately $300 per injection before any supplemental coverage. Patients with Medigap (Medicare Supplement) plans often have this coinsurance covered entirely, reducing their out-of-pocket to $0.

Medicare Advantage Plans

Medicare Advantage plans in Montana (offered by carriers like Humana, UnitedHealthcare, and Blue Cross Blue Shield) set their own formulary tiers and prior authorization rules. Some plans require documentation of bisphosphonate failure or intolerance before approving denosumab. The 2025 Endocrine Society clinical practice guideline recommends denosumab as a first-line option for patients at high fracture risk, and citing this guideline may support prior authorization requests 5.

Patients enrolled in Medicare Advantage should contact their plan's specialty pharmacy department to confirm coverage and expected copay before scheduling their injection.

The Amgen Savings Card: How It Works in Montana

Amgen offers a copay assistance program for commercially insured patients prescribed Prolia. The Amgen Savings Card can reduce out-of-pocket costs to as little as $0 per injection for eligible patients.

Eligibility Requirements

The program is available to patients with commercial or private insurance. It excludes Medicare, Medicaid, TRICARE, and other government-funded programs. Patients must have a valid prescription and receive treatment in the United States.

Enrollment and Redemption

Patients can enroll online at the manufacturer's website or by calling the support line. Once enrolled, the savings card is presented at the pharmacy or physician's office at the time of treatment. The card covers the difference between the patient's copay and the program's floor (typically $0 to $25).

Annual Limits

The Amgen Savings Card carries an annual benefit cap, which has historically ranged from $10,000 to $15,000 per year. Given that most commercially insured patients pay well under $600 annually in copays for two injections, the cap rarely comes into play for osteoporosis patients.

Montana patients without commercial insurance cannot use this card. They should instead explore Amgen's separate patient assistance program (Amgen Safety Net Foundation), which provides free medication to qualifying low-income, uninsured patients 6.

Compounded Denosumab in Montana

Licensed 503A compounding pharmacies in Montana can legally prepare compounded denosumab. This option exists under federal law (the Drug Quality and Security Act, Section 503A), which permits patient-specific compounding by state-licensed pharmacies when a valid prescription exists.

What 503A Compounding Means

A 503A pharmacy compounds medications on an individual-patient basis in response to a specific prescription. Unlike 503B outsourcing facilities (which produce larger batches), 503A pharmacies operate under state board of pharmacy oversight and do not require FDA registration for compounding activities 7.

Pricing Considerations

Compounded biologic preparations may cost less than brand-name products, but pricing is highly variable. Patients should confirm that the compounding pharmacy holds an active Montana Board of Pharmacy license and uses FDA-registered bulk drug substance suppliers. Because denosumab is a monoclonal antibody, compounding complexity is far greater than for small-molecule drugs.

Clinical Considerations

The FREEDOM extension study followed patients on denosumab for up to 10 years, showing sustained fracture-risk reduction and increasing bone mineral density throughout the treatment period 8. These long-term efficacy and safety data were generated using the branded Prolia formulation. No equivalent long-term data exist for compounded versions. Patients considering compounded denosumab should discuss this distinction with their prescriber.

Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute and co-author of the Endocrine Society's osteoporosis guidelines, has stated: "Denosumab discontinuation leads to rapid bone loss and a rebound increase in fracture risk. Consistent access to the medication, regardless of formulation source, is clinically essential" 5.

Telehealth Prescribing of Prolia in Montana

Montana permits telehealth prescribing of Prolia. A licensed prescriber can evaluate the patient via video or audio visit, review bone density results and lab work, and write the prescription remotely.

How the Process Works

The prescriber orders baseline labs (serum calcium, 25-hydroxyvitamin D, renal function) and reviews a current DXA scan. If the patient meets criteria for denosumab therapy, the prescription is sent to a specialty pharmacy or the patient's local clinic for administration. The actual injection still requires an in-person visit, since denosumab is a subcutaneous injection typically given by a healthcare provider.

Why This Matters in Montana

Montana covers 147,040 square miles with a population of roughly 1.1 million. Many residents live hours from the nearest endocrinology or rheumatology practice. Telehealth removes the consultation barrier while the injection itself can be administered by a local primary care provider, visiting nurse, or rural health clinic.

The American Association of Clinical Endocrinology (AACE) 2020 guideline supports initiating osteoporosis pharmacotherapy based on telehealth evaluation when in-person assessment is impractical 9.

Discount Programs and Additional Savings Strategies

Beyond the Amgen Savings Card, several other avenues can reduce Prolia costs for Montana residents.

Prescription Discount Platforms

GoodRx, RxSaver, and similar platforms aggregate negotiated rates from pharmacy benefit managers. These rates apply to uninsured or cash-pay patients. Discounts on specialty biologics like denosumab are typically modest (5% to 15%) compared to the deep discounts available on generic oral medications, but they can still save $75 to $225 per injection.

340B Drug Pricing Program

Federally qualified health centers (FQHCs) and certain hospitals in Montana participate in the 340B program, which requires manufacturers to sell outpatient drugs at significantly reduced prices to qualifying facilities. Patients treated at 340B-eligible sites may benefit from lower facility charges, though the savings structure depends on how each facility passes 340B pricing to patients 10.

Montana has multiple 340B-eligible facilities, including community health centers in Billings, Great Falls, Helena, and tribal health facilities across the state.

State Pharmaceutical Assistance

Montana does not operate a standalone state pharmaceutical assistance program (SPAP) for osteoporosis medications. However, the Montana Department of Public Health and Human Services maintains a list of patient assistance resources, and individual hospitals may offer charity care or financial assistance for high-cost medications.

Stopping Denosumab: The Rebound Fracture Risk

Cost pressures sometimes lead patients to skip or discontinue denosumab injections. This carries real clinical danger. A post-hoc analysis of the FREEDOM trial found that patients who discontinued denosumab experienced a rapid decline in bone mineral density back to pre-treatment levels within 12 to 18 months, with vertebral fracture rates rising to levels higher than baseline 11.

The European Medicines Agency issued a safety warning in 2017 specifically about rebound vertebral fractures after denosumab discontinuation 12. Current guidelines recommend transitioning to an oral or intravenous bisphosphonate (such as zoledronic acid) if denosumab must be stopped, to preserve bone density gains.

As the Endocrine Society guideline states: "Patients who discontinue denosumab should receive follow-on antiresorptive therapy to prevent the rebound increase in bone turnover and loss of BMD" 5.

Montana patients facing cost barriers should explore every assistance option before missing a scheduled dose. A six-month gap can undo years of bone density gains.